MedPacto, Inc. (KOSDAQ:A235980) announced a private placement of 328,588 registered convertible preferred stocks of the face value of KRW 500 per stock at an issue price of KRW 91,300 per stock for gross proceeds of KRW 30,000,084,400 through third-party allocation, on December 24, 2020. The transaction will include participation from Cape-Centum No. 6 New Technology Business Fund for 115,008 stocks, Friend New Technology Business Fund No. 38 for 82,146 stocks, Meritz Alpha View New Technology Finance Association No. 2 for 98,576 stocks and Ace Mercury New Technology Fund No. 12 for 32,858 stocks. The preferred stocks bear a dividend of 1% per annum. The preferred stocks are convertible into 328,588 common shares and the conversion request period is from January 15, 2022 till January 15, 2024. The transaction has been approved by the board of directors of the company. The securities to be issued are subject to a lock-up period of one year. The payment date of the transaction is January 15, 2021.